| 216 | 7 | 8 |
| 下载次数 | 被引频次 | 阅读次数 |
恶性胸腔积液(malignant pleural effusion,MPE)是指由原发胸膜肿瘤或其他部位的肿瘤转移至胸膜引起的胸腔积液,常常表现为进行性呼吸困难、咳嗽、肺不张、胸痛及发热等不适症状。几乎所有的恶性肿瘤均可出现MPE。在临床上,肺癌所引起MPE最为常见,约占1/3。目前MPE治疗方法很多,但往往是低效的,仅仅能缓解相关症状。血管内皮生长因子(vascular endothelial growth factor,VEGF)是肿瘤血管生成的调节因子,通过刺激血管生成,激活宿主血管内皮细胞参与肿瘤生长的整个过程。目前针对VEGF的血管靶向药物如恩度、贝伐珠单抗已开发并应用于多种恶性肿瘤的治疗,越来越多临床数据表明,血管靶向药物对MPE的治疗是有效且安全的。就VEGF在非小细胞肺癌(non-small cell lung cancer,NSCLC)相关性MPE中的表达及诊断、病理机制、临床治疗及预后等方面予以综述。
Abstract：Malignant pleural effusion(MPE)refers to the pleural effusion caused by primary tumors or metastases tumor from other parts of the body to the pleura. The common clinical symptoms of MPE include progressive dyspnea,cough,atelectasis,chest pain,and fever. It can occur in almost all types of malignant tumors;however,lung cancer is the most common cause of MPE,accounting for about 1/3 of the clinical cases. Although there are many therapeutic approaches currently available for MPE,they are usually inefficient and many can only alleviate the symptoms of the patients.Vascular endothelial growth factor(VEGF)has now been recognized as one of the most important regulatory factors in tumor angiogenesis,participating in the entire process of tumor growth through its function of stimulating tumor angiogenesis,it can activate host vascular endothelial cells,and promote malignant proliferation. The new drugs targeting VEGF,such as Endostar and Bevacizumab,have been developed and applied for the treatment of a variety of tumors. Data of recent clinical studies demonstrate that the medicines targeting VEGF are effective and safe for the clinical treatment of MPE. Therefore,VEGF-targeting represents a promising strategy for the diagnosis and treatment of MPE. This review briefly summarized recent prog-ress of VEGF on diagnosis,pathogenesis,clinical treatment and prognosis of MPE in patients with non-small cell lung cancer(NSCLC).
[1]CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[2]PENZ E,WATT K N,HERGOTT C A,et al.Management of malignant pleural effusion:challenges and solutions[J].Cancer Manag Res,2007,9:229-241.
[3]施焕中.规范恶性胸腔积液的诊断与治疗[J].中华内科杂志,2014,53(3):166-167.
[4]ZACHARY I.Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor[J].Am J Physiol Cell Physiol,2001,280(6):C1375-1386.
[5]IDE A G,BAKER N H,WARREN S L.Vascularization of the brown pearce rabbit epithelioma transplant as seen in the transparent ear chamber[J].Am J Roentgenol,1939,42:891-899.
[6]FOLKMAN J.Tumor angiogenesis:therapeutic implications[J].N Engl J Med,1971,285(21):1182-1186.
[7]SENGER D R,GALLI S J,DVORAK A M,et al.Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid[J].Science,1983,219:983-985.
[8]FERRARA N,HENZEL W J.Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular myocytes[J].Biochem Biophys Res Commun,1989,161:851-858.
[9]DE VRIES C,ESCOBEDO J A,UENO H,et al.The fms-like tyrosine kinase,a receptor for vascular endothelial growth factor[J].Science,1992,255:989-991.
[10]HARMEY J H,BOUCHIER-HAYES D.Vascular endothelial growth factor(VEGF),a survival factor for tumor cells:implications for anti-angiogenic therapy[J].Bioessays,2002,24:280-283.
[11]BRADSHAW M,MANSFIELD A,PEIKERT T.The role of vascular endothelial growth factor in the pathogenesis,diagnosis and treatment of malignant pleural effusion[J].Curr Oncol Rep,2013,15:207-216.
[12]ZANG J,HU Y,XU X,et al.Elevated serum levels of vascular endothelial growth factor predict a poor prognosis of platinumbased chemotherapy in non-small cell lung cancer[J].Onco Targets Ther,2017,10:409-415.
[13]POPPER H H.Progression and metastasis of lung cancer[J].Cancer Metastasis Rev,2016,35:75-91.
[14]HU C P.Interpretation of expert consensus 2014 on diagnosis and treatment of malignant pleural effusion[J].Chinese Journal of Practical Internal Medicine,2015,3(1):1-2.
[15]DVORAK H F.Vascular permeability factor/vascular endothelial growth factor:a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy[J].J Clin Oncol,2002,20:4368-4380.
[16]FAFLIORA E,HATZOGLOU C,GOURGOULIANIS K I,et al.Systematic review and meta-analysis of vascular endothelial growth factor as a biomarker for malignant pleural effusions[J].Physiol Rep,2016,4:e12978.
[17]SRIRAM K B,RELAN V,CLARKE B E,et al.Diagnostic molecular biomarkers for malignant pleural effusions[J].Future Oncol,2011,7:737-752.
[18]GU Y,ZHANG M,LI G H,et al.Diagnostic values of vascular endothelial growth factor and epidermal growth factor receptor for benign and malignant hydrothorax[J].Chin Med J,2015,128:305-309.
[19]NAM H S.Malignant pleural effusion:medical approaches for diagnosis and management[J].Tuberc Respir Dis,2014,76:211-217.
[20]CHEN Y,LIANG B,ZHAO Y J,et al.Transcription expression and clinical significance of vascular endothelial growth factor m RNA and endostatin m RNA in pleural effusions of patients with lung cancer[J].Diagn Cytopathol,2012,40:287-291.
[21]JIANG B,WU G P,ZHAO Y J,et al.Transcription expression and clinical significance of TTF-1 m RNA in pleural effusion of patients with lung cancer[J].Diagn Cytopathol,2008,36:849-854.
[22]PALAORO L A,BLANCO A M,GAMBONI M,et al.Usefulness of ploidy,agnor and immunocytochemistry for differentiating benign and malignant cells in serous effusions[J].Cytopathology,2007,18:33-39.
[23]LIGHT R W.Pleural effusions[J].Med Clin North Am,2011,95(6):1055-1070.
[24]刘秋芳.VEGF联合CEA应用晚期NSCLC恶性胸腔积液临床价值探讨[J].实用肿瘤学杂志,2013,27(2):156-159.
[25]STATHOPOULOS G T,KALOMENIDIS I.Malignant pleural effusion:tumor-host interactions unleashed[J].Am J Respir Crit Care Med,2012,186:487-492.
[26]HAMED E A,EL-NOWEIHI A M,MOHAMED A Z,et al.Mahmoud A.Vasoactive mediators(VEGF and TNFalpha)in patients with malignant and tuberculous pleural effusions[J].Respirology,2010,9(1):81-86.
[27]GERBER H P,FERRARA N.Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies[J].Cancer Res,2005,65:671-680.
[28]NUMNUM T M,ROCCONI R P,WHITWORTH J,et al.The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma[J].Gynecol Oncol,2006,102:425-428.
[29]FERRARA N,GERBER H P,LECOUTER J.The biology of VEGF and its receptors[J].Nat Med,2003,9:669-676.
[30]HICKLIN D J,ELLIS L M.Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis[J].J Clin Oncol,2005,23:1011-1027.
[31]ZACHARY I.Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor[J].Am J Physiol Cell Physiol,2001,280:C1375-1386.
[32]PRITCHARD-JONES R O,DUNN D B,QIU Y,et al.Expression of VEGF(xxx)b,the inhibitory isoforms of VEGF,in malignant melanoma[J].Br J Cancer,2007,97:223-230.
[33]FERRARA N.Vascular endothelial growth factor:basic science and clinical progress[J].Endocr Rev,2004,25:581-611.
[34]VOELKEL N F,VANDIVIER R W,TUDER R M.Vascular endothelial growth factor in the lung[J].Am J Physiol Lung Cell Moistiol,2006,290(2):L209-221.
[35]SEMENZA G L.Targeting HIF-1 for cancer therapy[J].Nat Rev Cancer,2003,3:721-732.
[36]MAYERHOFER M,VALENT P,SPERR W R,et al.BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator,hypoxia induciblefactor-1alpha,through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin[J].Blood,2002,100:3767-3775.
[37]LOEFFLER S,FAYARD B,WEIS J,et al.Interleukin-6 induces transcriptional activation of vascular endothelial growth factor(VEGF)in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1[J].Int J Cancer,2005,115:202-213.
[38]COHEN T,NAHARI D,CEREM L W,et al.Interleukin 6 induces the expression of vascular endothelial growth factor[J].JBiol Chem,1996,271:736-741.
[39]WóJCIK E,JAKUBOWICZ J,SKOTNICKI P,et al.IL-6 and VEGF in small cell lung cancer patients[J].Anticancer Res,2010,30:1773-1778.
[40]严俊,江莺,许惠利.恩度治疗恶性胸腔积液的研究进展[J].实用癌症杂志,2012(5):538-539.
[41]O′REILLY M S,BOEHM T,SHING Y,et al.Endostatin:an endogenous inhibitor of angiogenesis and tumor growth[J].Cell,1997,88:277-285.
[42]HAYES A J,LI L Y,LIPPMAN M E.Antivascular therapy:a new approach to cancer treatment[J].BMJ,1999,318:853-856.
[43]XU X,MAO W,CHEN Q,et al.Endostar,a modified recombinant human endostatin,suppresses angiogenesis through inhibition of Wnt/β-catenin signaling pathway[J].PLo S One,2014,9:e107463.
[44]RONG B,YANG S,LI W,et al.Systematic review and meta-analysis of Endostar(rh-endostatin)combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer[J].World J Surg Oncol,2012,10:170.
[45]MOHAJERI A,SANAEI S,KIAFAR F,et al.The challenges of recombinant endostatin in clinical application:focus on the different expression systems and molecular bioengineering[J].Adv Pharm Bull,2017,7:21-34.
[46]SHICHIRI M,HIRATA Y.Antiangiogenesis signals by endostatin[J].FASEB J,2001,15:1044-1053.
[47]HAJITOU A,GRIGNET C,DEVY L,et al.Antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells[J].FASEB J,2002,16:1802-1804.
[48]LI D H,LIU Q G,WANG H P,et al.Study on recombinant human endostatin in the treatment of malignant pleural effusion in the elderly[J].Shaanxi Med J(China),2015,44:1138-1139.
[49]MURAKAMI A,TABATA C,TABATA R,et al.Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma[J].Oncol Lett,2012,3:581-585.
[50]MA X,YAO Y,YUAN D,et al.Endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice[J].PLo S One,2012,7:e53449.
[51]QIN S,YANG L,LIANG J,et al.Prospective,randomized,multicenter clinical study of endometrial and cisplatin in the treatment of malignant pleural effusion[J].Chin J Clin Oncol,2017,22:193-202.
[52]HU X,SHI Y,WANG H,et al.A clinical study on intra-thoracic chemotherapy of recombinant human endostatin combined with cisplatin for malignant pleural effusion[J].Clin Med J,2015,3:23-27.
[53]WEI H,QIN S,YIN X,et al.Endostar inhibits ascites formation and prolonged survival in mouse models of malignant ascites[J].Oncol Lett,2015,9:2694-2700.
[54]秦叔逵,刘秀峰,王琳,等.重组人血管内皮抑素与化疗联合治疗肺外晚期恶性肿瘤的临床研究[J].临床肿瘤学杂志,2012,34(5):426-428.
[55]KISKER O,BECKER C M,PROX D,et al.Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model[J].Cancer Res,2011,61:7669-7674.
[56]秦美林.顺铂联合恩度胸腔灌注治疗晚期非小细胞肺癌恶性胸腔积液的临床观察[J].中国实用医药,2016,11(26):228-229.
[57]徐杰,徐大亮,李绪斌,等.重组人血管内皮抑素联合化疗治疗非小细胞肺癌恶性胸腔积液的疗效观察[J].中国临床肿瘤,2014,41(24):1573-1576.
[58]黄莉.恩度联合顺铂治疗非小细胞肺癌恶性胸腔积液的临床观察[J].吉林医学,2014,35(19):4308-4309.
[59]杨勇,林润英,曹官铭.恩度联合顺铂治疗非小细胞肺癌恶性胸腔积液近远期疗效[J].中国药业,2013,22(19):21-22.
[60]刘维,哈敏文,殷南昌,等.恩度联合顺铂胸腔内注射治疗非小细胞肺癌恶性胸腔积液临床研究[J].山东医药,2010,50(8):79-80.
[61]黄柬.恩度联合顺铂胸腔内灌注治疗恶性胸腔积液疗效观察[J].实用临床医药杂志,2010,14(13):63-64.
[62]李文燕.恩度胸腔内灌注治疗恶性胸腔积液疗效观察[J].医药论坛杂志,2011,32(7):170-171.
[63]涂建仁,黄淑娟,王美.重组人血管内皮抑素联合顺铂胸腔内注射治疗非小细胞肺癌恶性胸腔积液临床研究[J].实用癌症杂志,2014,29(12):1592-1594.
[64]YAN J,JIANG Y,XU H.Endu treatment of malignant pleural effusion[J].Practical J Cancer,2012,27:538-539.
[65]ZHOU C,WU Y L,CHEN G,et al.BEYOND:a randomized,double-blind,placebo-controlled,multicenter,phase III study of first-line carboplatin/paclitaxel plus Bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer[J].J Clin Oncol,2015,33:2197-2204.
[66]SHIBUYA M.Vascular endothelial growth factor(VEGF)and its receptor(VEGFR)signaling in angiogenesis:a crucial target for anti-and pro-angiogenic therapies[J].Genes Cancer,2011,2(12):1097-1105.
[67]WU Z,WU Q,SUN D,et al.Progress in response prediction for bevacizumab in anti-tumor therapy[J].Prog Modern Biomed,2014,14:4570-4573.
[68]GUAN F,LI Z,YUAN S,et al.Current status and clinical application of bevacizumab[J].Chinese Scientists,2016,12:30.
[69]TAMIYA M,TAMIYA A,YAMADORI T,et al.Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion[J].Med Oncol,2013,30(3):1-6.
[70]LI H T,PEI C H,LIAO T L,et al.Pleural fluid osteopontin,vascular endothelial growth factor,and urokinasetype plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion:a prospective cohort study[J].BMC Cancer,2016,16(1):1-8.
[71]林凤华,苏伟平,金润女.贝伐单抗联合顺铂治疗非小细胞肺癌恶性胸腔积液临床研究[J].临床军医杂志,2016,44(7):698-700.
[72]迟晶,白阳,陈虹.贝伐单抗联合卡铂治疗非小细胞肺癌恶性胸腔积液临床研究[J].中国临床药理学杂志,2016,22(13):813-816.
[73]陈雷,夏书月.贝伐单抗联合顺铂治疗非小细胞肺癌恶性胸腔积液的效果和安全性[J].上海交通大学学报(医学版),2015,35(8):1194-1198.
[74]曲博,姜威,周志明.贝伐单抗联合顺铂治疗非小细胞肺癌恶性胸腔积液临床研究[J].中国医科大学学报,2015,44(7):648-652.
[75]黄彬.贝伐单抗和顺铂联合治疗非小细胞肺癌恶性胸腔积液的疗效评价[J].国际呼吸杂志,2016,36(11):814-817.
[76]韩娜,张孟贤,于世英,等.贝伐单抗联合培美曲塞/顺铂治疗非鳞癌性非小细胞肺癌恶性胸腔积液的临床研究[J].华中科技大学学报(医学版),2013,42(5):588-591.
[77]刘华平,龚传平,屈磊,等.贝伐单抗联合顺铂/培美曲塞治疗NSCLC恶性胸腔积液的疗效[J].西南国防医药,2016,26(12):1148-1150.
[78]ZHANG Y,YU L K,LU G J,et al.Prognostic values of VEGF and endostatin with malignant pleural effusions in patients with lung cancer[J].Asian Pac J Caner Prev,2014,15:8435-8440.
基本信息:
DOI：10.16389/j.cnki.cn42-1737/n.2018.01.017
中图分类号:R730.2
引用信息:
[1]陈瑶,卢宏达.NSCLC相关的恶性胸腔积液中VEGF表达及临床意义研究进展[J].江汉大学学报(自然科学版),2018,46(01):87-96.DOI:10.16389/j.cnki.cn42-1737/n.2018.01.017.
基金信息: